Some Facts on BioNTech SE Shares

Large-cap Health Care company BioNTech SE has logged a 2.5% change today on a trading volume of 480,216. The average volume for the stock is 692,062.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Based in Mainz, Germany the company has 5,500 full time employees and a market cap of $26,113,677,312.

The company is now trading -32.43% away from its average analyst target price of $160.36 per share. The 17 analysts following the stock have set target prices ranging from $107.36 to $258.46, and on average give BioNTech SE a rating of buy.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2022-12-31 17,310,600 9,434,400 54.5 0.48
2021-12-31 18,976,700 10,292,500 54.24 1621.9
2020-12-31 482,325 15,198 3.15 101.91
2019-12-31 108,589 -179,056 -164.89 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.